Open an account

Bayer AG

BAYZF · XETRA

$49.38+$0.58 (+1.19%)TodayMarket closed ·
No price history for this range.

About BAYZF

Bayer AG engages in the business of life science fields of healthcare and nutrition. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 88,078 full-time employees. The firm's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.

Employees
88,078
Headquarters
Leverkusen, Nordrhein-Westfalen
Listed
Nov 28, 1997
Sector
Health Care
Industry
Pharmaceuticals
Website
bayer.com

BAYZF key statistics

Market cap
42.64B
Price-earnings ratio
0.00
Dividend yield
0.31%
Average volume
6.63K
Volume
1.53K
Open price
$49.38
High today
$49.38
Low today
$49.38
52 Week high
$61.38
52 Week low
$30.00

Bayer AG (BAYZF) at a glance

As of Oct 20, 2026, Bayer AG (BAYZF) shares are priced at $49.38, giving the company a market cap of 42.64B, a price-to-earnings ratio of 0.00 and a dividend yield of 0.31%.

Volume so far is 1.53K shares, below the average of 6.63K shares a day.

Over the past year Bayer AG has ranged from $30.00 to $61.38, and now sits 62% of the way up that range.

Bayer AG met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.95 per share against an estimate of $0.8275.

BAYZF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 23.5% on average.

  1. Q3 FY24: reported $0.24 per share against an estimate of $0.2901
  2. Q4 FY24: reported $1.05 per share against an estimate of $1.02
  3. Q1 FY25: reported $2.49 per share against an estimate of $2.44
  4. Q2 FY25: reported $1.23 per share against an estimate of $0.8431
  5. Q3 FY25: reported $0.57 per share against an estimate of $0.333
  6. Q4 FY25: reported $0.62 per share against an estimate of $0.508
  7. Q1 FY26: reported $2.48 per share against an estimate of $2.35
  8. Q2 FY26: reported $0.95 per share against an estimate of $0.8275

BAYZF news

  • Press releaseBusiness Wire

    Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

  • Press releaseBusiness Wire

    Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause

  • Press releaseBusiness Wire

    U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

  • Press releaseBusiness Wire

    Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States

  • Press releaseBusiness Wire

    Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle

  • Press releaseBusiness Wire

    MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option

  • Press releaseBusiness Wire

    U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer

  • Press releaseBusiness Wire

    Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.